Logo

LifeSpan Licenses DrugTarget Database to Pfizer

Dec 21, 2005

NEW YORK, Dec. 21 (GenomeWeb News) - LifeSpan BioSciences today announced that Pfizer has signed an agreement to license its DrugTarget database.

 

The multi-year agreement will enable Pfizer to gain access to the database, which includes information on more than 3,200 genes, along with 852 immunohistochemistry reports with localization information on more than 400 potential drug targets.

 

Both LifeSpan and Pfizer said they would add targets to the database over time.

 

Financial details were not discussed.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.